Suppr超能文献

肾细胞癌中白细胞介素-2激活的肿瘤浸润淋巴细胞的T细胞功能

T cell functions of IL-2-activated tumor-infiltrating lymphocytes from renal cell carcinoma.

作者信息

Morita T, Salmeron M A, Hayakawa K, Swanson D A, von Eschenbach A C, Itoh K

机构信息

Department of Immunology, University of Texas M. D. Anderson Cancer Center, Houston 77030.

出版信息

Reg Immunol. 1992 Jul-Aug;4(4):225-35.

PMID:1476875
Abstract

Renal cell carcinoma (RCC) is one of the few cancers partially sensitive to biotherapy. However, involvement of T cell immunity in host-defense against autologous tumor cells remains unclear. This manuscript investigated T cell functions of interleukin-2 (IL-2)-activated tumor-infiltrating lymphocytes (TILs) from human RCCs by studying their oligoclonality, cytotoxicity, and cytokine production. IL-2-activated RCC-TILs from 17 of 33 cases (52%) (p < 0.01 vs. IL-2-activated patients' peripheral blood mononuclear cells, PBMC) displayed oligoclonal expansion as determined by seven different monoclonal antibodies (mAbs) to T cell receptor (TCR) V alpha or beta regions after 2 to 5 weeks in culture. By comparison, IL-2-activated PBMC from only 1 of 15 healthy donors (7%), 3 of 23 patients (13%), and IL-2-activated lymphocytes from nontumorous kidney from 1 of 8 (12.5%) cases (V beta 5.1) did. Specifically, IL-2-activated RCC-TILs showed oligoclonal expansion of V alpha 2+ cells (8/33 cases, p < 0.05 vs. IL-2-activated patient's PBMC), V beta 5.1+ cells (6/33), V beta 8+ cells (4/33), V beta 12+ cells (4/33), and V beta 6.7+ cells (2/33). Oligoclonal expansion of plural TCR V regions was observed in 6 of 33 cases. IL-2-activated RCC-TILs from 4 of 16 cases produced higher levels of interferon-gamma (IFN-gamma) in culture with autologous tumor cells than with allogeneic tumor cells. Those from 11 of 16 cases did not produce IFN-gamma in response to autologous tumor cells, and the remaining case produced it in a major histocompatibility complex (MHC)-nonrestricted manner. IL-2-activated RCC-TILs with oligoclonal expansion in 4 of 5 cases showed IFN-gamma production in response to the corresponding anti-TCR V region mAb as well as anti-CD3 mAb. IL-2 and IL-4 were not detected in any cases tested. IL-2-activated RCC-TILs displayed cytotoxicity relatively restricted to autologous tumor cells in only 1 of the 16 cases evaluated, MHC-nonrestricted cytotoxicity in 12 cases, NK activity in one case and no cytotoxicity in two cases. In summary, IL-2-activated RCC-TILs demonstrated the oligoclonality in approximately half of the cases (17 of 33, 52%), but rarely displayed either autologous tumor-specific-IFN-gamma production (4 of 16 cases) or -cytotoxicity (1 of 16 cases).

摘要

肾细胞癌(RCC)是少数对生物疗法部分敏感的癌症之一。然而,T细胞免疫在宿主抵御自体肿瘤细胞中的作用仍不清楚。本研究通过研究白细胞介素-2(IL-2)激活的人肾细胞癌肿瘤浸润淋巴细胞(TILs)的寡克隆性、细胞毒性和细胞因子产生,来探究其T细胞功能。33例中的17例(52%)(与IL-2激活的患者外周血单个核细胞,PBMC相比,p < 0.01)的IL-2激活的肾细胞癌TILs在培养2至5周后,通过7种不同的针对T细胞受体(TCR)Vα或β区域的单克隆抗体(mAb)检测显示出寡克隆扩增。相比之下,15名健康供体中只有1例(7%)、23例患者中的3例(13%)的IL-2激活的PBMC,以及8例中的1例(12.5%)(Vβ5.1)的非肿瘤性肾组织的IL-2激活的淋巴细胞出现这种情况。具体而言,IL-2激活的肾细胞癌TILs显示Vα2+细胞(8/33例,与IL-2激活的患者PBMC相比,p < 0.05)、Vβ5.1+细胞(6/33)、Vβ8+细胞(4/33)、Vβ12+细胞(4/33)和Vβ6.7+细胞(2/33)的寡克隆扩增。33例中的6例观察到多个TCR V区域的寡克隆扩增。16例中的4例IL-2激活的肾细胞癌TILs在与自体肿瘤细胞共培养时比与异体肿瘤细胞共培养时产生更高水平的干扰素-γ(IFN-γ)。16例中的11例对自体肿瘤细胞无IFN-γ产生,其余1例以主要组织相容性复合体(MHC)非限制性方式产生。5例中有4例出现寡克隆扩增的IL-2激活的肾细胞癌TILs对相应的抗TCR V区域mAb以及抗CD3 mAb有IFN-γ产生。在任何测试病例中均未检测到IL-2和IL-4。在评估的16例中,只有1例IL-2激活的肾细胞癌TILs显示出相对局限于自体肿瘤细胞的细胞毒性,12例具有MHC非限制性细胞毒性,1例具有NK活性,2例无细胞毒性。总之,IL-2激活的肾细胞癌TILs在大约一半的病例(33例中的17例,52%)中表现出寡克隆性,但很少表现出自体肿瘤特异性IFN-γ产生(16例中的4例)或细胞毒性(16例中的1例)。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验